In fact, even some “techno-libertarians,” who believe that government should not regulate new developments in biotechnology, have supported the US Food and Drug Administration’s decision – outlined in a scathing letter to 23andMe CEO Anne Wojcicki last November – to prevent the firm from marketing its tests pending further scientific analysis. “I’d like to be able to argue that the [FDA] is wantonly standing in the way of entrepreneurism and innovation by cracking down on 23andMe,” wrote Matthew Herper in Forbes.